Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Anika Therapeutics, Inc. (ANIK): Are Hedge Funds Right About This Stock?

Anika Therapeutics, Inc. (NASDAQ:ANIK) was in 6 hedge funds’ portfolio at the end of December. ANIK shareholders have witnessed a decrease in activity from the world’s largest hedge funds lately. There were 6 hedge funds in our database with ANIK positions at the end of the previous quarter.

In the financial world, there are many metrics market participants can use to watch publicly traded companies. A pair of the most innovative are hedge fund and insider trading interest. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the best money managers can outperform the broader indices by a superb margin (see just how much).


Just as important, bullish insider trading activity is another way to parse down the marketplace. As the old adage goes: there are plenty of incentives for an insider to downsize shares of his or her company, but just one, very simple reason why they would behave bullishly. Many empirical studies have demonstrated the impressive potential of this method if you know what to do (learn more here).

With these “truths” under our belt, it’s important to take a peek at the recent action regarding Anika Therapeutics, Inc. (NASDAQ:ANIK).

What does the smart money think about Anika Therapeutics, Inc. (NASDAQ:ANIK)?

Heading into 2013, a total of 6 of the hedge funds we track were long in this stock, a change of 0% from the third quarter. With hedge funds’ capital changing hands, there exists a select group of notable hedge fund managers who were upping their holdings substantially.

When looking at the hedgies we track, Jim Simons’s Renaissance Technologies had the most valuable position in Anika Therapeutics, Inc. (NASDAQ:ANIK), worth close to $3.9 million, accounting for less than 0.1%% of its total 13F portfolio. The second largest stake is held by Robert B. Gillam of McKinley Capital Management, with a $1 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Other hedgies that are bullish include Gregory Fraser, Rudolph Kluiber, and Timothy Kroch’s GRT Capital Partners, Israel Englander’s Millennium Management and D. E. Shaw’s D E Shaw.

Due to the fact that Anika Therapeutics, Inc. (NASDAQ:ANIK) has witnessed falling interest from the entirety of the hedge funds we track, it’s easy to see that there was a specific group of money managers that elected to cut their entire stakes at the end of the year. At the top of the heap, Chuck Royce’s Royce & Associates dropped the biggest position of the 450+ funds we key on, worth an estimated $2.6 million in stock., and Peter Algert and Kevin Coldiron of Algert Coldiron Investors was right behind this move, as the fund dumped about $0.4 million worth. These bearish behaviors are intriguing to say the least, as total hedge fund interest stayed the same (this is a bearish signal in our experience).

Insider trading activity in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Bullish insider trading is at its handiest when the company we’re looking at has experienced transactions within the past 180 days. Over the last six-month time period, Anika Therapeutics, Inc. (NASDAQ:ANIK) has seen zero unique insiders purchasing, and 2 insider sales (see the details of insider trades here).

Let’s go over hedge fund and insider activity in other stocks similar to Anika Therapeutics, Inc. (NASDAQ:ANIK). These stocks are BioTime, Inc. (NYSEAMEX:BTX), Immunomedics, Inc. (NASDAQ:IMMU), Sinovac Biotech Ltd. (NASDAQ:SVA), Corcept Therapeutics Incorporated (NASDAQ:CORT), and Verastem Inc (NASDAQ:VSTM). This group of stocks are the members of the biotechnology industry and their market caps are similar to ANIK’s market cap.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.